Report of the Cent Gardes HIV Vaccine Conference: The B-cell response to HIV Part 2: Non-neutralizing antibodies. Fondation Mérieux Conference Center, Veyrier du Lac, France 5-7 November 2012.

Marc P. Girard, Valentina Picot, Christophe Longuet, Gary J. Nabel

Research output: Contribution to journalArticlepeer-review

Abstract

The Cent Gardes Conference on HIV Vaccines took place on November 5-7, 2012 at the Fondation Mérieux Conference Center, Annecy, France. The aim of the meeting was to review the B cell response to human immunodeficiency virus-1 (HIV-1) infection and immunization, from broadly neutralizing antibodies (bnAbs) to non-neutralizing antibodies (n-nAbs). This paper, Part 2 of the report, focuses on potentially protective n-nAbs. Evidence was presented that n-nAbs may effectively contribute to protection against HIV, as illustrated by the recent RV144 efficacy trial. They can either act as IgGs by mediating antibody-dependent cellular cytotoxicity (ADCC) involving Fc effector functions, or as IgAs, particularly dimeric IgA1s, which can inhibit virus transcytosis through monocellular epithelia and could play an important role in mucosal immunity.

Original languageEnglish (US)
Pages (from-to)2984-2987
Number of pages4
JournalVaccine
Volume31
Issue number29
DOIs
StatePublished - Jun 24 2013
Externally publishedYes

Keywords

  • Antibody-dependent cellular cytotoxicity
  • HIV vaccines
  • Mucosal immunity
  • Transcytosis inhibitory antibodies

ASJC Scopus subject areas

  • Immunology and Microbiology(all)
  • Infectious Diseases
  • Public Health, Environmental and Occupational Health
  • veterinary(all)
  • Molecular Medicine

Fingerprint Dive into the research topics of 'Report of the Cent Gardes HIV Vaccine Conference: The B-cell response to HIV Part 2: Non-neutralizing antibodies. Fondation Mérieux Conference Center, Veyrier du Lac, France 5-7 November 2012.'. Together they form a unique fingerprint.

Cite this